Aplan Peter D
Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 8901 Wisconsin Ave, Bethesda, Maryland, MD 20889-5105, USA.
Trends Genet. 2006 Jan;22(1):46-55. doi: 10.1016/j.tig.2005.10.002. Epub 2005 Oct 28.
Non-random chromosomal translocations are frequently associated with a variety of cancers, particularly hematologic malignancies and childhood sarcomas. In addition to their diagnostic utility, chromosomal translocations are increasingly being used in the clinic to guide therapeutic decisions. However, the mechanisms that cause these translocations remain poorly understood. Illegitimate V(D)J recombination, class switch recombination, homologous recombination, non-homologous end-joining and genome fragile sites all have potential roles in the production of non-random chromosomal translocations. In addition, mutations in DNA-repair pathways have been implicated in the production of chromosomal translocations in humans, mice and yeast. Although initially surprising, the identification of these same oncogenic chromosomal translocations in peripheral blood from healthy individuals strongly suggests that the translocation is not sufficient to induce malignant transformation, and that complementary mutations are required to produce a frank malignancy.
非随机染色体易位常与多种癌症相关,尤其是血液系统恶性肿瘤和儿童肉瘤。除了具有诊断价值外,染色体易位在临床上越来越多地用于指导治疗决策。然而,导致这些易位的机制仍知之甚少。异常V(D)J重组、类别转换重组、同源重组、非同源末端连接和基因组脆弱位点在非随机染色体易位的产生中都可能发挥作用。此外,DNA修复途径中的突变与人类、小鼠和酵母中染色体易位的产生有关。尽管最初令人惊讶,但在健康个体外周血中发现同样的致癌染色体易位强烈表明,这种易位不足以诱导恶性转化,还需要互补突变才能产生明显的恶性肿瘤。